Insulet Corporation Announces the Sale of $85 Million of Common

Insulet Corporation Announces the Sale of $85 Million of Common Stock 
BEDFORD, MA -- (Marketwire) -- 01/03/13 --  Insulet Corporation
(NASDAQ: PODD), the leader in tubeless insulin pump technology with
its OmniPod Insulin Management System, today announced the sale of
$85 million of its common stock pursuant to an underwriting agreement
with Canaccord Genuity Inc. The last reported sale price of Insulet's
common stock as reported by the Nasdaq Global Market on January 3,
2013 was $21.72 per share.  
Insulet intends to use the net proceeds to fund sales and marketing
activities associated with its next generation OmniPod System, to
fund product development and for general corporate purposes. Closing
of the offering is expected to occur on or about January 9, 2013,
subject to customary closing conditions. In addition, Insulet has
granted the underwriter a 30-d
ay option to purchase additional shares
of common stock equal to up to 15% of the number of shares of common
stock sold in the offering to cover over-allotments, if any. 
Canaccord Genuity Inc. is acting as sole book-running manager for the
offering. 
The offering is being made pursuant to an effective shelf
registration statement filed with the Securities and Exchange
Commission. This press release does not constitute an offer to sell
or a solicitation of an offer to buy securities nor shall there be
any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Copies of the prospectus supplement, when available,
and accompanying prospectus may be obtained by sending a request to
the offices of Canaccord Genuity, Attn: Syndicate Department, 99 High
Street, 12th Floor, Boston, MA 02110, phone: 1-800-225-6201.
Alternatively, you may get these documents for free by visiting EDGAR
on the SEC website at www.sec.gov. 
About Insulet Corporation  
Insulet Corporation is an innovative medical device company dedicated
to making the lives of people with diabetes easier. Through its
OmniPod Insulin Management System, Insulet seeks to expand the use of
insulin pump therapy among people with insulin-dependent diabetes.
The OmniPod is a revolutionary and easy-to-use tubeless insulin pump
that features just two parts and fully-automated cannula insertion.
Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor
for diabetes products and supplies, delivered through a high touch
customer service model. Founded in 2000, Insulet Corporation is based
in Bedford, Mass. For more information, please visit:
http://www.myomnipod.com. 
Forward-Looking Statements  
This press release contains forward-looking statements within the
meaning of the federal securities laws, including the expected
closing date of this offering. These forward-looking statements are
based on Insulet's current expectations and beliefs concerning future
developments and their potential effects on it. There can be no
assurance that future developments affecting it will be those that it
has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties described in the
section entitled "Risk Factors" in Insulet's Annual Report on Form
10-K for the year ended December 31, 2011 and Item 1A in Insulet's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2012, and in its other filings from time to time filed with the
Securities and Exchange Commission. Should one or more of these risks
or uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking
statements. 
Contact: 
Stephanie Marks for Insulet Corporation
ir@insulet.com
212-843-0211 
 
 
Press spacebar to pause and continue. Press esc to stop.